IN THE SPECIFICATION:

Please replace the Sequence Listing on pages 30-43 with the following text:

-- SEQUENCE LISTING

<110> Kyocera Corporation

     Nishimura, Yoshihiko

     Suzuki, Yoshihisa

     Tanihara , Masao

<120> A Peptide and Osteogenetic Accelerator

<130> 81918-0001

<140> 09/439,779

<141> 1999-11-12

<160> 11

<170> PatentIn version 3.1

<210> 1

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthesized peptide

<220>

<221> MISC_FEATURE

<222> (6)..(6)

<223> Xaa=Lys, Ser or Thr

<220>

<221> MISC_FEATURE

<222> (7)..(7)

<223> Xaa=Ile or Val

<220>

<221> MISC_FEATURE

<222> (10)..(10)

<223> Xaa=Ala or Pro

```
<220>

<221>   MISC_FEATURE

<222>   (13)..(13)

<223>   Xaa=Ala or Val


<220>

<221>   MISC_FEATURE

<222>   (18)..(18)

<223>   Xaa=Ser or Asn


<400>   1

Asn Ser Val Asn Ser Xaa Xaa Pro Lys Xaa Cys Cys Xaa Pro Thr Glx
1                   5                   10                  15


Leu Xaa Ala Ile
            20


<210>   2

<211>   21

<212>   PRT

<213>   Artificial Sequence


<220>

<223>   Synthesized peptide
```

```
<220>

<221>  MISC_FEATURE

<222>  (6)..(6)

<223>  Xaa=Lys, Ser or Thr


<220>

<221>  MISC_FEATURE

<222>  (7)..(7)

<223>  Xaa=Ile or Val


<220>

<221>  MISC_FEATURE

<222>  (10)..(10)

<223>  Xaa=Ala or Pro


<220>

<221>  MISC_FEATURE

<222>  (13)..(13)

<223>  Xaa=Ala or Val


<220>
```

<221> MISC_FEATURE

<222> (18)..(18)

<223> Xaa=Ser or Asn

<400> 2

Asn Ser Val Asn Ser Xaa Xaa Pro Lys Xaa Cys Cys Xaa Pro Thr Glx
1   5   10   15

Leu Xaa Ala Ile Ser
            20

<210> 3

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthesized peptide

<220>

<221> MISC_FEATURE

<222> (7)..(7)

<223> Xaa=Lys, Ser or Thr

<220>

<221>   MISC_FEATURE

<222>   (8)..(8)

<223>   Xaa=Ile or Val

<220>

<221>   MISC_FEATURE

<222>   (11)..(11)

<223>   Xaa=Ala or Pro

<220>

<221>   MISC_FEATURE

<222>   (14)..(14)

<223>   Xaa=Ala or Val

<220>

<221>   MISC_FEATURE

<222>   (19)..(19)

<223>   Xaa=Ser or Asn

<400>   3

Asn Ser Val Asn Pro Glu Xaa Xaa Pro Lys Xaa Cys Cys Xaa Pro Thr

```
1                    5                      10                      15
```

```
Glx Leu Xaa Ala Ile
              20
```

<210> 4

<211> 22

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthesized peptide

<220>

<221> MISC_FEATURE

<222> (7)..(7)

<223> Xaa=Lys, Ser or Thr

<220>

<221> MISC_FEATURE

<222> (8)..(8)

<223> Xaa=Ile or Val

<220>

<221>   MISC_FEATURE

<222>   (11)..(11)

<223>   Xaa=Ala or Pro

<220>

<221>   MISC_FEATURE

<222>   (14)..(14)

<223>   Xaa=Ala or Val

<220>

<221>   MISC_FEATURE

<222>   (19)..(19)

<223>   Xaa= Ser or Asn

<400>   4

Asn Ser Val Asn Pro Glu Xaa Xaa Pro Lys Xaa Cys Cys Xaa Pro Thr
1   5   10   15

Glx Leu Xaa Ala Ile Ser
            20

<210>   5

<211>   18

<212>   PRT

<213>   Artificial Sequence

<220>

<223>   Synthesized peptide

<220>

<221>   MISC_FEATURE

<222>   (4)..(4)

<223>   Xaa=Lys, Ser or Thr

<220>

<221>   MISC_FEATURE

<222>   (5)..(5)

<223>   Xaa=Ile or Val

<220>

<221>   MISC_FEATURE

<222>   (8)..(8)

<223>   Xaa=Ala or Pro

<220>

<221> MISC_FEATURE

<222> (11)..(11)

<223> Xaa=Ala or Val

<220>

<221> MISC_FEATURE

<222> (16)..(16)

<223> Xaa=Ser or Asn

<400> 5

Ile Asn Ser Xaa Xaa Pro Lys Xaa Cys Cys Xaa Pro Thr Glx Leu Xaa
1   5   10   15

Ala Ile

<210> 6

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthesized peptide

<220>

<221>   MISC_FEATURE

<222>   (4)..(4)

<223>   Xaa=Lys, Ser or Thr

<220>

<221>   MISC_FEATURE

<222>   (5)..(5)

<223>   Xaa=Ile or Val

<220>

<221>   MISC_FEATURE

<222>   (8)..(8)

<223>   Xaa=Ala or Pro

<220>

<221>   MISC_FEATURE

<222>   (11)..(11)

<223>   Xaa=Ala or Val

<220>

<221>   MISC_FEATURE

<222> (16)..(16)

<223> Xaa=Ser or Asn

<400> 6

Ile Asn Ser Xaa Xaa Pro Lys Xaa Cys Cys Xaa Pro Thr Glx Leu Xaa
1   5   10   15

Ala Ile Ser

<210> 7

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthesized peptide

<220>

<221> MISC_FEATURE

<222> (5)..(5)

<223> Xaa=Lys, Ser or Thr

<220>

<221>   MISC_FEATURE

<222>   (6)..(6)

<223>   Xaa=Ile or Val

<220>

<221>   MISC_FEATURE

<222>   (9)..(9)

<223>   Xaa=Ala or Pro

<220>

<221>   MISC_FEATURE

<222>   (12)..(12)

<223>   Xaa=Ala or Val

<220>

<221>   MISC_FEATURE

<222>   (17)..(17)

<223>   Xaa=Ser or Asn

<400>   7

Ile Asn Pro Glu Xaa Xaa Pro Lys Xaa Cys Cys Xaa Pro Thr Glx Leu
1   5   10   15

Xaa Ala Ile

<210>   8

<211>   20

<212>   PRT

<213>   Artificial Sequence

<220>

<223>   Synthesized peptide

<220>

<221>   MISC_FEATURE

<222>   (5)..(5)

<223>   Xaa=Lys, Ser or Thr

<220>

<221>   MISC_FEATURE

<222>   (6)..(6)

<223>   Xaa=Ile or Val

<220>

<221>   MISC_FEATURE

<222>   (9)..(9)

<223>   Xaa=Ala or Pro

<220>

<221>   MISC_FEATURE

<222>   (12)..(12)

<223>   Xaa=Ala or Val

<220>

<221>   MISC_FEATURE

<222>   (17)..(17)

<223>   Xaa=Ser or Asn

<400>   8

Ile Asn Pro Glu Xaa Xaa Pro Lys Xaa Cys Cys Xaa Pro Thr Glx Leu
1   5   10   15

Xaa Ala Ile Ser
            20

<210>   9

<211>   20

<212>   PRT

<213> Artificial Sequence

<220>

<223> Synthesized peptide

<400> 9

```
Asn Ser Val Asn Ser Lys Ile Pro Lys Ala Cys Cys Val Pro Thr Glu
1               5               10              15
```

```
Leu Ser Ala Ile
            20
```

<210> 10

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthesized peptide

<400> 10

```
Asn Ser Val Asn Ser Ser Ile Pro Lys Ala Cys Cys Val Pro Thr Glu
1               5               10              15
```

```
Leu Ser Ala Ile
            20
```

<210> 11

<211> 20

<212> PRT

<213> Artificial

<400> 11

Ile Asn Pro Glu Thr Val Pro Lys Pro Cys Cys Ala Pro Thr Gln Leu
1   5   10   15

Asn Ala Ile Ser --
            20